Cargando…

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

Primary sclerosing cholangitis (PSC) represents a major unmet medical need. In a phase II double‐blind, placebo‐controlled study, we tested the safety and efficacy of cilofexor (formerly GS‐9674), a nonsteroidal farnesoid X receptor agonist in patients without cirrhosis with large‐duct PSC. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trauner, Michael, Gulamhusein, Aliya, Hameed, Bilal, Caldwell, Stephen, Shiffman, Mitchell L., Landis, Charles, Eksteen, Bertus, Agarwal, Kosh, Muir, Andrew, Rushbrook, Simon, Lu, Xiaomin, Xu, Jun, Chuang, Jen‐Chieh, Billin, Andrew N., Li, Georgia, Chung, Chuhan, Subramanian, G. Mani, Myers, Robert P., Bowlus, Christopher L., Kowdley, Kris V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767458/ https://www.ncbi.nlm.nih.gov/pubmed/30661255 http://dx.doi.org/10.1002/hep.30509

Ejemplares similares

Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers
por: Younis, Islam R., et al.
Publicado: (2023)

PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis
por: Trauner, Michael, et al.
Publicado: (2023)

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH
por: Xu, Jun, et al.
Publicado: (2023)

Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist
por: Younis, Islam, et al.
Publicado: (2023)

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis
por: Schramm, Christoph, et al.
Publicado: (2022)

Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis
por: Trauner, Michael, et al.
Publicado: (2019)

Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2(-/-) mouse model of sclerosing cholangitis
por: Fuchs, Claudia D., et al.
Publicado: (2023)

A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis
por: Gindin, Yevgeniy, et al.
Publicado: (2021)

Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury
por: Petrescu, Anca D., et al.
Publicado: (2021)

The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model
por: Schwabl, Philipp, et al.
Publicado: (2021)

Neutralization of IL-15 abrogates experimental immune-mediated cholangitis in diet-induced obese mice
por: Reyes, José L., et al.
Publicado: (2018)

Arbutin Alleviates the Liver Injury of α-Naphthylisothiocyanate-induced Cholestasis Through Farnesoid X Receptor Activation
por: Wu, Peijie, et al.
Publicado: (2021)

Mechanism and Active Components of Qingre Lidan Tablets Alleviate Intrahepatic Cholestasis by Activating the Farnesoid X Receptor
por: Xia, Yafei, et al.
Publicado: (2022)

Promoter DNA Methylation of Farnesoid X Receptor and Pregnane X Receptor Modulates the Intrahepatic Cholestasis of Pregnancy Phenotype
por: Cabrerizo, Romina, et al.
Publicado: (2014)

Recent advances in understanding and managing cholestasis
por: Wagner, Martin, et al.
Publicado: (2016)

Intrahepatic Cholestasis of Pregnancy Levels of Sulfated Progesterone Metabolites Inhibit Farnesoid X Receptor Resulting in a Cholestatic Phenotype
por: Abu-Hayyeh, Shadi, et al.
Publicado: (2013)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses
por: Zhou, Qifan, et al.
Publicado: (2023)

Calculus Bovis Sativus Improves Bile Acid Homeostasis via Farnesoid X Receptor-Mediated Signaling in Rats With Estrogen-Induced Cholestasis
por: Xiang, Dong, et al.
Publicado: (2019)

Progressive familial intrahepatic cholestasis — farnesoid X receptor deficiency due to NR1H4 mutation: A case report
por: Czubkowski, Piotr, et al.
Publicado: (2021)

β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor
por: Klag, Thomas, et al.
Publicado: (2018)

Paeoniflorin alleviates 17α-ethinylestradiol-induced cholestasis via the farnesoid X receptor-mediated bile acid homeostasis signaling pathway in rats
por: Wang, Rulin, et al.
Publicado: (2022)

Molecular alterations of canalicular transport systems in experimental models of cholestasis: possible functional correlations.
por: Trauner, M.
Publicado: (1997)

Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement
por: Yu, Helen, et al.
Publicado: (2018)

Baicalin Protects Against 17α-Ethinylestradiol-Induced Cholestasis via the Sirtuin 1/Hepatic Nuclear Receptor-1α/Farnesoid X Receptor Pathway
por: Yang, Jinyu, et al.
Publicado: (2020)

Systemic Causes of Cholestasis
por: deLemos, Andrew S., et al.
Publicado: (2013)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

NLRP3 receptor contributes to protection against experimental antigen-mediated cholangitis
por: González, Marisol Ibet, et al.
Publicado: (2020)

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
por: Mueller, Michaela, et al.
Publicado: (2015)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Inhibition of farnesoid X receptor signaling shows beneficial effects in human obesity
por: Gonzalez, Frank J., et al.
Publicado: (2015)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Cholestasis in Benign Recurrent Intrahepatic Cholestasis 2
por: Arthur Lorio, Eric, et al.
Publicado: (2020)

Behind the scenes of GS: preventing and curing - the GS-SE group
por: CERN, GS-SE
Publicado: (2013)

Differential effects of norUDCA and UDCA in obstructive cholestasis in mice
por: Fickert, Peter, et al.
Publicado: (2013)

Nonsteroidal Anti-Inflammatory Drugs, Gastroprotection, and Benefit–Risk
por: Moore, Robert Andrew, et al.
Publicado: (2014)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study
por: Eksteen, Bertus, et al.
Publicado: (2020)

Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study
por: Bowlus, Christopher L., et al.
Publicado: (2023)

Nonsteroidal Antiinflammatory Drugs are Associated with Increased Aortic Stiffness
por: Claridge, Martin, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_graqovbvj230i8qej1k64ba3b4